PMID- 29609951
OWN - NLM
STAT- MEDLINE
DCOM- 20190715
LR  - 20190715
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 18
IP  - 5
DP  - 2018 Oct
TI  - Bone Metastasis in Advanced Breast Cancer: Analysis of Gene Expression 
      Microarray.
PG  - e1117-e1122
LID - S1526-8209(17)30777-2 [pii]
LID - 10.1016/j.clbc.2018.03.001 [doi]
AB  - BACKGROUND: Approximately 30% to 40% of breast cancer recurrences involve bone 
      metastasis (BM). Certain genes have been linked to BM; however, none have been 
      able to predict bone involvement. In this study, we analyzed gene expression 
      profiles in advanced breast cancer patients to elucidate genes that can be used 
      to predict BM. PATIENTS AND METHODS: A total of 92 advanced breast cancer 
      patients, including 46 patients with BM and 46 patients without BM, were 
      identified for this study. Immunohistochemistry and gene expression analysis was 
      performed on 81 formalin-fixed paraffin-embedded samples. Data were collected 
      through medical records, and gene expression of 200 selected genes compiled from 
      6 previous studies was performed using NanoString nCounter. RESULTS: Genetic 
      expression profiles showed that 22 genes were significantly differentially 
      expressed between breast cancer patients with metastasis in bone and other organs 
      (BM+) and non-BM, whereas subjects with only BM showed 17 significantly 
      differentially expressed genes. The following genes were associated with an 
      increasing incidence of BM in the BM+ group: estrogen receptor 1 (ESR1), GATA 
      binding protein 3 (GATA3), and melanophilin with an area under the curve (AUC) of 
      0.804. In the BM group, the following genes were associated with an increasing 
      incidence of BM: ESR1, progesterone receptor, B-cell lymphoma 2, Rab escort 
      protein, N-acetyltransferase 1, GATA3, annexin A9, and chromosome 9 open reading 
      frame 116. ESR1 and GATA3 showed an increased strength of association with an AUC 
      of 0.928. CONCLUSION: A combination of the identified 3 genes in BM+ and 8 genes 
      in BM showed better prediction than did each individual gene, and this 
      combination can be used as a training set.
CI  - Copyright (c) 2018 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Cosphiadi, Irawan
AU  - Cosphiadi I
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. 
      Electronic address: cosphiadi@gmail.com.
FAU - Atmakusumah, Tubagus D
AU  - Atmakusumah TD
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
FAU - Siregar, Nurjati C
AU  - Siregar NC
AD  - Department of Pathology Anatomy, Universitas Indonesia/Cipto Mangunkusumo General 
      Hospital, Jakarta, Indonesia.
FAU - Muthalib, Abdul
AU  - Muthalib A
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Universitas Indonesia/Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
FAU - Harahap, Alida
AU  - Harahap A
AD  - Department of Clinical Pathology, Universitas Indonesia/Cipto Mangunkusumo 
      General Hospital, Jakarta, Indonesia.
FAU - Mansyur, Muchtarruddin
AU  - Mansyur M
AD  - Department of Public Health, Universitas Indonesia/Cipto Mangunkusumo General 
      Hospital, Jakarta, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20180308
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*genetics
MH  - Bone Neoplasms/*genetics/*secondary
MH  - Breast Neoplasms/*genetics/*pathology
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Middle Aged
MH  - Transcriptome
OTO - NOTNLM
OT  - Advanced breast cancer
OT  - Bone metastasis
OT  - ESR1
OT  - Gene expression profile
OT  - NanoString microarray
EDAT- 2018/04/04 06:00
MHDA- 2019/07/16 06:00
CRDT- 2018/04/04 06:00
PHST- 2017/11/27 00:00 [received]
PHST- 2018/02/26 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/04/04 06:00 [pubmed]
PHST- 2019/07/16 06:00 [medline]
PHST- 2018/04/04 06:00 [entrez]
AID - S1526-8209(17)30777-2 [pii]
AID - 10.1016/j.clbc.2018.03.001 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2018 Oct;18(5):e1117-e1122. doi: 10.1016/j.clbc.2018.03.001. 
      Epub 2018 Mar 8.